Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma

Multiple myeloma is the second most common plasma cell malignancy, characterized by uncontrolled proliferation of plasma cells within the bone marrow. ELREXFIO™ (elranatamab-bcmm) is a recently FDA-approved drug for relapsed and refractory multiple myeloma. The progression of multiple myeloma involv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rais, Taruba, Khan, Afsheen, Riaz, Rumaisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571667/
https://www.ncbi.nlm.nih.gov/pubmed/37840703
http://dx.doi.org/10.1177/20363613231207483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571667/
https://www.ncbi.nlm.nih.gov/pubmed/37840703
http://dx.doi.org/10.1177/20363613231207483

Ejemplares similares